Last reviewed · How we verify
Albuterol/salbutamol
Albuterol is a beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle, causing relaxation and bronchodilation.
Albuterol is a beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle, causing relaxation and bronchodilation. Used for Acute bronchospasm and reversible airway obstruction in asthma, Chronic obstructive pulmonary disease (COPD) with reversible airway obstruction, Exercise-induced bronchoconstriction prevention.
At a glance
| Generic name | Albuterol/salbutamol |
|---|---|
| Also known as | short-acting β2-adrenergic agonists, bronchodilators, Proventil HFA, ProAir®, ProAir HFA |
| Sponsor | GlaxoSmithKline |
| Drug class | Short-acting beta-2 adrenergic agonist (SABA) |
| Target | Beta-2 adrenergic receptor (ADRB2) |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Mechanism of action
Albuterol activates beta-2 adrenergic receptors on bronchial smooth muscle cells, triggering a cascade that increases intracellular cAMP levels. This leads to smooth muscle relaxation and rapid airway dilation, relieving bronchoconstriction. It is a short-acting beta-2 agonist (SABA) used for acute relief of airway obstruction.
Approved indications
- Acute bronchospasm and reversible airway obstruction in asthma
- Chronic obstructive pulmonary disease (COPD) with reversible airway obstruction
- Exercise-induced bronchoconstriction prevention
Common side effects
- Tremor
- Headache
- Nervousness/anxiety
- Palpitations
- Muscle cramps
- Tachycardia
Key clinical trials
- A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations (PHASE3)
- High Flow Nasal Cannula Rates in Pediatric Asthma (NA)
- Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma (PHASE2)
- Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis (PHASE1, PHASE2)
- A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma (PHASE3)
- A 12-Week Treatment Study to Evaluate the Effectiveness of Albuterol Multidose Dry Powder Inhaler With Integrated Electronic Module Digital System (eMDPI DS) in Participants13 Years or Older With Asthma (PHASE4)
- A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma (PHASE3)
- GRANITE: Airsupra Effectiveness in the Real World
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Albuterol/salbutamol CI brief — competitive landscape report
- Albuterol/salbutamol updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI